Table 5.
Overall technical success and clinical diagnostic outcome in our cohort, with the aggregated literature until 2017 (11).
| Technical Success and Clinical Diagnostic Outcome | Our Study | Laleman (11) |
|---|---|---|
| Diagnostic success n (%) | 39/41 (95.12) | 631/691 (91.3) |
| SpyBite biopsy success n (%) | 21/23 (91.3) | 485/515 (94.2) |
| Therapeutic success n (%) | 33/41 (80.5) | 213/244 (87.3) |
| Visual Diagnosis | ||
| Sensitivity | 93.3% (95% CI: 67.98–98.89) | 90.8 % (95 % CI 84.8–95) |
| Specificity | 87.5% (95% CI: 47.38–97.93) | 90.9 % (95 % CI 85.4–94.8) |
| PPV | 93.3% (95% CI: 67.98–98.89) | 89.5 % (95 % CI 83.3–94.0) |
| NPV | 87.5% (95% CI: 47.38–97.93) | 92.0 % (95 % CI 86.7–95.7) |
| Accuracy | 91% | 90.8% |
| Biopsy Diagnosis | ||
| Sensitivity | 80% (95% CI: 57.16–97.80 %) | 72.4 % (95 % CI 64.7–79.3) |
| Specificity | 87.5 ( 95% CI: 58.93–100) | 100 % (95 % CI 96.8–100) |
| PPV | 100% (95% CI: 73.35–100.00) | 100 % (95 % CI 96.8–100) |
| NPV | 77.7% (95% CI: 40.06–96.53) | 72.4 % (95 % CI 64.7–79) |
| Accuracy | 82.6% (19/23) | 84% |
| Brush Cytology Diagnosis | ||
| Sensitivity | 26.6%, | N.A |
| Specificity | 75% | N.A |
| PPV | 100% (95% CI: 40.23–100.00) | N.A |
| NPV | 42.8% (95% CI: 17.76–71.08 ) | N.A |
| Accuracy | 43.5% (10/23). | N.A |
| Visual/Biopsy Diagnosis Concordance | 56% (13/23) for malignancy 43.4% (10/23) for benign changes |
74 % (17/23), 85 % (41/48) (5,12) |